intellia logo
Opening a new era of medicine
Read about our groundbreaking clinical data using CRISPR genome editing
News Update
May 7, 2021
Intellia Therapeutics Announces First Quarter 2021 Financial Results
Overview

Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.

Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.

Learn About Our Mission
Programs & Pipeline

Each one of us together for patients

We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.

Join Us.
See how you can change life stories with genome editing
Learn More
Full-Spectrum Blog
Farewell to Sickle Cell Disease in the Developing World
Farewell to Sickle Cell Disease in the Developing World
Read the full article
Follow Us on Social Media
May 31, 2021

Happy #MemorialDay! Today, we’d like to remember the men and women who have given their lives in service to our country, and thank all our current service members for all you do. https://t.co/SE8HR9JH5k

View on Twitter
May 27, 2021

A warm welcome to our 8 summer interns! They will help with a number of initiatives across the company in departments such as Finance, Human Resources, Portfolio & Strategy, Communications and Investor Relations and more! #OneIntellia #IamIntellia https://t.co/Q7MsqjSMlw

View on Twitter
Menu